Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 10/20 | 0.66 |
| ▸ | PARP10 | Q53GL7 | 13/20 | 0.63 |
| ▸ | PARP1 | P09874 | 5/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 6/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27446376 | 0.90 | PARP11 (0.55) | PARP11PARP10PARP1PDPK1GRM5 | |
| SCHEMBL8162850 | 0.87 | PARP10 (0.63) | PARP11PARP10PARP1PDPK1GRM5 | |
| SCHEMBL25947316 | 0.83 | PARP11 (0.66) | PARP11PARP10PARP1PDPK1GRM5 | |
| SCHEMBL7901539 | 0.83 | CLK4 (0.49) | PARP11PARP10GRM5 | |
| SCHEMBL19386434 | 0.83 | PARP11 (0.61) | PARP11PARP10PARP1PDPK1GRM5 | |
| SCHEMBL20627544 | 0.83 | PARP11 (0.61) | PARP11PARP10PARP1PDPK1GRM5 | |
| SCHEMBL1725258 | 0.80 | PARP11 (0.58) | PARP11PARP10PARP1PDPK1GRM5 | |
| SCHEMBL23074494 | 0.80 | PARP11 (0.43) | PARP11PARP10PARP1F7F3 | |
| SCHEMBL19454258 | 0.80 | PARP11 (1.00) | PARP11PARP10PARP1PDPK1GRM5 | |
| SCHEMBL27445552 | 0.78 | PARP11 (0.52) | PARP11PARP10PARP1PDPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-9896443-B2 | Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-02-20 | — | — | US | disclosed |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-08-06 | — | — | US | disclosed |
| WO-2015073804-A2 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-05-21 | — | — | WO | disclosed |
| US-8716492-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-1682537-B1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8101778-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | PARP11 2630/4885PARP10 2961/4885PARP1 2987/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | PARP11 806/4885PARP10 748/4885PARP1 840/4885 |
| US-20150218150-A1 | PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, BAK1 | PARP11 1585/4885PARP10 2783/4885PARP1 1558/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | PARP11 992/4885PARP10 1341/4885PARP1 2786/4885 |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | PARP11 1983/4885PARP10 3118/4885PARP1 2958/4885 |
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | PARP11 1721/4885PARP10 1586/4885PARP1 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.